Codexis, Inc. (CDXS) Sets 12-Month High at $14.11

May 16, 2018 - By Loretta Love

Codexis, Inc. (NASDAQ:CDXS) Corporate Logo

During 2017 Q4 the big money sentiment decreased to 2.17. That’s change of 0.03, from 2017Q3’s 2.2. 3 investors sold all, 15 reduced holdings as Codexis, Inc. ratio dropped. 27 grew stakes while 12 funds bought stakes. Funds hold 28.02 million shares thus 9.42% more from 2017Q3’s 25.60 million shares.
Moreover, Prelude Capital Management Limited Liability Company has 0.03% invested in Codexis, Inc. (NASDAQ:CDXS). Stifel Financial Corporation reported 10,000 shs. 84,581 are held by Schwab Charles Inv Mngmt. Jpmorgan Chase, a New York-based fund reported 8,800 shs. Rhumbline Advisers reported 35,893 shs or 0% of all its holdings. Ameritas Inv Prtn owns 2,608 shs. Blair William Il holds 0.01% or 149,247 shs. Laurion Cap Management Limited Partnership invested 0% of its capital in Codexis, Inc. (NASDAQ:CDXS). Vanguard Inc owns 1.81 million shs for 0% of their capital. Guggenheim Capital Limited Liability Company accumulated 10,184 shs. Credit Suisse Ag has invested 0% of its capital in Codexis, Inc. (NASDAQ:CDXS). Vantage Investment Ltd stated it has 3,252 shs or 0.01% of all its holdings. Tower Rech Cap Lc (Trc) holds 0.01% in Codexis, Inc. (NASDAQ:CDXS) or 10,400 shs. Morgan Stanley holds 0% or 91,201 shs. Royal Retail Bank Of Canada holds 0% or 42,147 shs in its capital.

Codexis, Inc. registered $1.19 million net activity with 0 buys and 5 selling transactions since March 21, 2018. Another trade for 25,000 shs valued at $276,318 was sold by BARUCH THOMAS R. Smith David V had sold 6,000 shs worth $62,213. On Monday, March 26 WOLF DENNIS P had sold 41,666 shs worth $464,384. The insider NICOLS JOHN J sold 22,465 shs worth $259,828.

Codexis, Inc. (NASDAQ:CDXS) touched yearly high touching $14.11. Our price target is $15.24. Barchart.com reported it on May, 16. It has $751.49 million MC. At $15.24 stock price target, the company valuation changes by $60.12M more.

CDXS touched $14.11 during the last trading session after $0.86 change.Codexis, Inc. has 492,171 shares volume, 17.42% up from normal. CDXS is uptrending and has moved 125.77% since May 16, 2017. CDXS outperformed by 114.22% the S&P500.

On August, 8 is awaited Codexis, Inc. (NASDAQ:CDXS)’s earnings report, as reported by Faxor. Analysts expect change of 76.92 % or $0.10 from previous year’s $-0.13 earnings per share compared to current’s $-0.03 earnings per share. Wall Street predicts -70.00 % EPS growth as of August, 8.

Codexis, Inc. (NASDAQ:CDXS) Ratings Coverage

A total of 2 analysts rate Codexis (NASDAQ:CDXS) as follows: 2 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. The firm has $1600 highest and $11.5 lowest target. The avg target $13.75 is -2.55% below the last ($14.11) price. (NASDAQ:CDXS) has 2 ratings reports on May 16, 2018 according to StockzIntelligence. On Wednesday, May 16 the stock of Codexis, Inc. (NASDAQ:CDXS) has “Buy” rating given by Stephens. On Monday, March 12 the company was maintained by H.C. Wainwright.

A couple more Codexis, Inc. (NASDAQ:CDXS) news were released by: Seekingalpha.com which released on May 11, 2018 “Codexis’ (CDXS) CEO John Nicols on Q1 2018 Results – Earnings Call Transcript”, also Globenewswire.com on May 03, 2018 released “Codexis to Hold First Quarter 2018 Conference Call on May 10”, the next Globenewswire.com is “Codexis Reports First Quarter 2018 Financial Results” on May 10, 2018. Nasdaq.com has article titled “3 High-Growth Stocks That Are Just Getting Started”.

Codexis, Inc. discovers, develops, and sells protein catalysts.The company has $751.49 million market cap. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable clients to perform chemistry screening.Currently it has negative earnings. The firm also provides protein catalyst screening and protein engineering services.

Codexis, Inc. (NASDAQ:CDXS) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.